Navigation Links
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
Date:7/16/2009

dustry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

    CONTACTS:
    Tibotec
    Louise Mehrotra, Investor Relations
    (732) 524-6491

    Karen Manson, Media
    +44 1737 644 690 office
    +32 479 89 47 99 mobile


'/>"/>
SOURCE Tibotec Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Jan. 6, 2011 Viveve, Inc. , a ... has received the European CE (Conformite Europeenne) mark for ... treatment of laxity of the vaginal introitus (opening), after ...   http://photos.prnewswire.com/prnh/20110106/SF25673LOGO ) "The CE mark is ...
... VRUS ), announced today positive data from interim analyses ... 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the ... Pipeline Update and 2011 Highlights PSI-7977 ... pegylated interferon and ribavirin (Peg-IFN/RBV) in a Phase 2b study. This ...
Cached Medicine Technology:Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... 30, 2014 Daily Gossip magazine reveals ... anxiety and panic attacks under control with a simple ... review describes this new method as an anxiety ... attacks and overcome general anxiety related disorders. , ... the fact that it can be accessed by users ...
(Date:8/30/2014)... 30, 2014 Ticket Down ... Tennis Championship tickets in NYC. This popular ... US-OPEN-2014 for all day session, evening session, courtside seats, ... for this prestigious Grand Slam Tournament. , The 2014 ... , US Open Tennis Championship: Men's/Women's 3rd Round - ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Seniors Guide, the ... recently that focus on Alzheimer’s Disease, Dementia, and Memory ... to the public of being diagnosed with the Alzheimer’s, inspired ... movie, “I’ll Be Me”. The movie, out on October ... focusing on his diagnosis of the disease – which inspires ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... women volunteers got HIV during 6-month study , , TUESDAY, ... contains the antiretroviral drug tenofovir is safe for HIV-negative women ... 200 women in India and the United States. , This ... Microbicide Trials Network, looked at whether women were able to ...
... about digital signage? ... Watch for the Orange, MODESTO, Calif., Feb. 26 emebaVet, ... systems,integration, travels to Las Vegas this week where Vice President of,Technology ... excited to participate and speak at this year,s Digital Signage,Expo," says ...
... Center on Non-Resident Fathers and the Child Welfare ... been selected to,receive funding from the Administration of ... and Human Services from 2008 to 2011. The ... model intervention and,evaluation of child outcomes as the ...
... LSU researchers are taking what might be the most comprehensive ... from disaster. , The end goal of the project, which is ... be able to develop and use an index of coastal ... about ways to increase resilience in weaker areas. , ...
... to Provide ... Solid Basis for Interoperability, ORLANDO, Fla., Feb. 26 ... eHealth specialist,InterComponentWare (ICW), and Sun Microsystems, Inc. have joined as,foundation ... that is unique in the healthcare IT arena. The Open ...
... insurance to young,families, WASHINGTON, Feb. 26 While ... is also irreplaceable life and,disability insurance for young families, ... National Academy of Social Insurance (NASI)., About 6.5 ... of all U.S.,children - received part of their family ...
Cached Medicine News:Health News:HIV Drug in Microbicide Gel Safe for Daily Use 2Health News:emebaVet, LLC Talks Digital Signage in Vegas 2Health News:Non-Resident Fathers Project Selects Four National Sites for Funding to Increase Father Involvement and Improve Outcomes in Child Welfare 2Health News:Non-Resident Fathers Project Selects Four National Sites for Funding to Increase Father Involvement and Improve Outcomes in Child Welfare 3Health News:Non-Resident Fathers Project Selects Four National Sites for Funding to Increase Father Involvement and Improve Outcomes in Child Welfare 4Health News:Non-Resident Fathers Project Selects Four National Sites for Funding to Increase Father Involvement and Improve Outcomes in Child Welfare 5Health News:LSU researchers study coastal community bounce back 2Health News:Agfa HealthCare, InterComponentWare, and Sun Microsystems Join Open eHealth Foundation at HIMSS08 2Health News:Agfa HealthCare, InterComponentWare, and Sun Microsystems Join Open eHealth Foundation at HIMSS08 3Health News:Agfa HealthCare, InterComponentWare, and Sun Microsystems Join Open eHealth Foundation at HIMSS08 4Health News:Social Security Lifts 1.3 Million Children Out of Poverty 2
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... and a FAM-labeled probe that is designed to ... Type 1 and Type 2 polymerase gene. This ... FAM reporter dye like the Cepheid SmartCycler System. ... is comprised of a series of easy-to-use primer ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
Medicine Products: